BMS proposes acquisition of ImClone at $60/share

Bristol-Myers Squibb (BMS) has proposed to enter into an agreement to acquire ImClone Systems for $60.00 per share in cash, or a total payment of approximately $4.5 billion

J&J publish series of Aurora A/VEGFR-1 inhibitors

J&J have published a series of Aurora A/VEGFR-2 inhibitors

AstraZeneca publish series of CSF-1R inhibitors for the treatment of cancer

AstraZeneca have published a series of pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer

Amgen publish series of Indazole KDR/VEGFR-2 Inhibitors

Amgen have published a series of Indazole KDR/VEGFR-2 Inhibitors

Incyte report on INCB18424 and INCB28050 progress

In 2nd quarter results Incyte have provided an update on JAK2 inhibitors INC18424 and INCB28050

ARIAD commence Phase II trial of oral deforolimus in breast cancer

ARIAD have announced the initiation of a Phase II clinical trial of mTOR inhibitor Deforolimus in Patients with Metastatic, HER2-Positive Breast Cancer

Novartis publish series of CDC7 inhibitors

Novartis have published a series of 4-(1H-Indazol-5-yl)-6-phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors

Sunesis publish information on discovery of Aurora kinase inhibitor

Sunesis have published  data on an Aurora kinase inhibitor

PI3K inhibitor administration improves Doxorubicin activity in breast cancer cells

Preclinical data shows that administration of PI3K inhibitor LY294002 enhances the anticancer activity of doxorubicin on breast cancer cells in vitro

Pharmacopeia receive milestone from Wyeth in JAK3 collaboration

Pharmacopeia have received a milestone payment from Wyeth Pharmaceuticals for identifying a systemically administered JAK3 kinase inhibitor for the treatment of immunological and inflammatory diseases.